Trial reportKidney international2017
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
Abstract readRandomized Controlled Trial
In one paragraph
Trial report in Kidney international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 7 pooled it
7.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 7 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Serum and urine prognostic biomarkers for autosomal dominant polycystic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Therapeutic Potential of Ketogenic Interventions for Autosomal-Dominant Polycystic Kidney Disease: A Systematic Review.Nutrients · 2024Pooled it
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease.The Cochrane database of systematic reviews · 2024Pooled it
- Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2022Pooled it
- International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people.Nature reviews. Nephrology · 2019Guideline
- High sodium intake increases blood pressure and risk of kidney disease. From the Science of Salt: A regularly updated systematic review of salt and health outcomes (August 2016 to March 2017).Journal of clinical hypertension (Greenwich, Conn.) · 2018Pooled it
- Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials.Nutrients · 2018Pooled it
- Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Trial
- Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial.Cell reports. Medicine · 2023Trial
- The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.Scientific reports · 2021Trial
- Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2018Trial
- Modeling Complex Developmental Disease: The Case of Polycystic Kidney Disease.Journal of developmental biology · 2026Review
- KDIGO 2025 ADPKD guideline through pediatric eyes.Pediatric nephrology (Berlin, Germany) · 2026Article
- Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets.Current issues in molecular biology · 2026Review
- Nutritional considerations for designing ketogenic dietary interventions for people with Autosomal Dominant Polycystic Kidney Disease.Journal of nephrology · 2025Review
- Tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD): a multicenter real life Italian experience.Clinical kidney journal · 2025Article
- Comprehensive dietary patterns explain acquired cystic kidney disease risk through genetic and metabolomic mechanisms.Frontiers in nutrition · 2025Article
- Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease.Nutrients · 2024Review
- Sodium and water dynamics in the progression of chronic kidney disease: mechanisms and clinical significance.International urology and nephrology · 2024Review
- How Does ADPKD Severity Differ Between Family Members?Kidney international reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 1 country.
Vicente E TorresMayo Clinic College of Medicine, Rochester, Minnesota, USA. Electronic address: torres.vicente@mayo.edu.
Kaleab Z AbebeUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Robert W SchrierUniversity of Colorado Health Sciences Center, Denver, Colorado, USA.
Ronald D PerroneTufts Medical Center, Boston, Massachusetts, USA.
Arlene B ChapmanUniversity of Chicago, Chicago, Illinois, USA.
Alan S YuKansas University Medical Center, Kansas City, Kansas, USA.
William E BraunCleveland Clinic, Cleveland, Ohio, USA.
Theodore I SteinmanBeth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Godela BrosnahanUniversity of Colorado Health Sciences Center, Denver, Colorado, USA.
Marie C HoganMayo Clinic College of Medicine, Rochester, Minnesota, USA.
Frederic F RahbariEmory University School of Medicine, Atlanta, Georgia, USA.
Jared J GranthamKansas University Medical Center, Kansas City, Kansas, USA.
Kyongtae T BaeUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Charity G MooreCarolinas HealthCare System, Charlotte, North Carolina, USA.
Michael F FlessnerNational Institutes of Health, Bethesda, Maryland, USA.
Mayo Clinic · USUniversity Medical Center · USUniversity of Colorado Health · USUniversity of Pittsburgh · USBeth Israel Deaconess Medical Center · USCarolinas Healthcare System · USCleveland Clinic · USEmory University · USNational Institutes of Health · USTufts Medical Center · USUniversity of Chicago · US
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MHARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4MMAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7MZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI ALBERT, RICHARD K · 1985 to 2008
$52.6MClinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0MColorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0MMayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MZINC STATUS AND T CELL DISORDER IN MILD HUMAN ZINC DEFICIENCYM01RR001032 · NCRR · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PASCUAL-LEONE, ALVARO · 1985 to 2008
$32.3MZESTRIL VS. VERAPAMIL IN THE TREATMENT OF HYPERTENSIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 1985 to 2006
$30.4MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0MNCATS NIH HHS UL1 TR000001NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR001064NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001102NCRR NIH HHS M01 RR000039NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000054NCRR NIH HHS M01 RR000585NCRR NIH HHS M01 RR001032NCRR NIH HHS M01 RR023940NCRR NIH HHS UL1 RR024150NCRR NIH HHS UL1 RR024989NCRR NIH HHS UL1 RR025008NCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1 RR025780NCRR NIH HHS UL1 RR033179NIDDK NIH HHS P30 DK090728NIDDK NIH HHS P30 DK106912NIDDK NIH HHS R01 DK044863NIDDK NIH HHS U01 DK056956NIDDK NIH HHS U01 DK062401NIDDK NIH HHS U01 DK062402NIDDK NIH HHS U01 DK062408NIDDK NIH HHS U01 DK062410NIDDK NIH HHS U01 DK062411NIDDK NIH HHS U01 DK082230
Abstract
The CRISP study of polycystic kidney disease (PKD) found that urinary sodium excretion associated with the rate of total kidney volume increase. Whether sodium restriction slows the progression of Autosomal Dominant PKD (ADPKD) is not known. To evaluate this we conducted a post hoc analysis of the HALT-PKD clinical trials of renin-angiotensin blockade in patients with ADPKD. Linear mixed models examined whether dietary sodium affected rates of total kidney volume or change in estimated glomerular filtration rate (eGFR) in patients with an eGFR over 60 ml/min/1.73 m
Indexed as
Diet, Sodium-RestrictedGlomerular Filtration RateAdolescentAdultAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsBlood PressureDisease ProgressionFemaleHumansKidneyMaleMiddle AgedNatriuresisPolycystic Kidney, Autosomal DominantAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsSodium Chloride, Dietaryautosomal dominant polycystic kidney diseaseCKD progressionkidney volumelow-salt dietsodium
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.